Case-only evidence and high cost proved insufficient for targeted import funding in Poland. #HTA #EvidenceSynthesis #RegulatoryAffairs https://www.mattheneus.com/editorial/aotmit-xuriden-dee50-targeted-import-case-series-cost-rejection-2026-09-30

Hospital screening can look cost-saving—until one fragile effectiveness assumption moves. #HTA #HealthEconomics #EvidenceSynthesis https://www.mattheneus.com/editorial/carbapenemase-screening-effectiveness-cost-saving-transferability-2026-10-13

Multinational clinical-trial advice is becoming a permanent part of Europe’s regulatory pathway. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/ema-act-eu-pre-application-advice-permanent-ctis-2026-10-08

Scotland accepts atogepant for acute migraine after an indirect class comparison—what the Bayesian network evidence means for HTA decisions. https://www.mattheneus.com/editorial/smc-atogepant-aquipta-acute-migraine-bayesian-network-comparison-2026-10-12 #HTA #NMA #EvidenceSynthesis #Pharma

Automated evidence retrieval is moving from promise to methodological scrutiny in German HTA. https://www.mattheneus.com/editorial/iqwig-ga2605-search-source-screening-methods-2026-10-13 #HTA #EvidenceSynthesis #RegulatoryAffairs

A mortality signal is not yet an implementation case: what payers still need from convective dialysis evidence. #HTA #EvidenceSynthesis #HealthEconomics https://www.mattheneus.com/editorial/cochrane-convective-dialysis-mortality-signal-implementation-evidence-2026-10-13

Top-ranked doesn’t mean decision-ready: why transfusion-threshold evidence in acute brain injury still needs an audit. https://www.mattheneus.com/editorial/acute-brain-injury-transfusion-threshold-bayesian-nma-evidence-audit-2026-10-12 #HTA #NMA #EvidenceSynthesis

Poland backs coordinated rare-disease care despite rejecting a stand-alone neurofibromatosis benefit. #HTA #HealthEconomics https://www.mattheneus.com/editorial/aotmit-neurofibromatosis-coordinated-care-separate-benefit-rejection-rare-disease-centres-2026-10-07

The UK has authorised once-weekly Onswik for adults with type 2 diabetes—an important shift in basal insulin convenience. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/mhra-onswik-insulin-efsitora-weekly-type2-diabetes-qwint-authorisation-2026-10-13

Why did Germany find aficamten’s added benefit unproven against mavacamten? Endpoint choice and indirect-comparison limits matter. https://www.mattheneus.com/editorial/iqwig-aficamten-obstructive-hcm-mavacamten-endpoint-itc-nonproof-2026-08-27 #HTA #MAIC #EvidenceSynthesis

Elahere’s direct survival evidence still leaves adjusted-comparison uncertainty where decision-makers need clarity. https://www.mattheneus.com/editorial/smc-elahere-mirvetuximab-mirasol-maic-survival-model-2026-10-12 #HTA #MAIC #EvidenceSynthesis #Pharma

In type 3 von Willebrand disease, bleeding-rate assumptions can decide whether prophylaxis looks cost-saving. https://www.mattheneus.com/editorial/type-3-von-willebrand-prophylaxis-cost-saving-bleeding-rate-assumptions-2026-10-13 #HTA #HealthEconomics #EvidenceSynthesis

Medical cannabis may help insomnia—but Cochrane says evidence across nine studies remains uncertain. https://www.mattheneus.com/editorial/cochrane-medical-cannabis-insomnia-nine-studies-low-certainty-2026-10-13 #HTA #EvidenceSynthesis #RWE

Why did SMC decline Yorvipath despite clinical response? The value case—and economic model—fell short. https://www.mattheneus.com/editorial/smc-yorvipath-palopegteriparatide-hypoparathyroidism-non-recommendation-economic-model-2026-10-12 #HTA #HealthEconomics #Pharma

Hearing-intervention value cases can miss costs that change the economic story. https://www.mattheneus.com/editorial/hearing-intervention-economic-model-missing-costs-2026-10-12 #HTA #HealthEconomics #EvidenceSynthesis

SMC accepts obinutuzumab for lupus nephritis—but comparator uncertainty remains in the evidence base. https://www.mattheneus.com/editorial/smc-gazyvaro-obinutuzumab-lupus-nephritis-regency-nma-flare-model-2026-10-12 #HTA #NMA #EvidenceSynthesis #Pharma

A joint neurology guideline maps adult migraine prevention across 217 trials—and highlights the active-comparison evidence gap. https://www.mattheneus.com/editorial/aan-ahs-adult-migraine-prevention-guideline-217-trials-active-comparison-gap-2026-10-13 #HTA #EvidenceSynthesis #Pharma

Cost-effectiveness evidence doesn’t carry a passport: insulin value claims can shift sharply across countries. #HTA #HealthEconomics #EvidenceSynthesis https://www.mattheneus.com/editorial/type-1-diabetes-insulin-cost-effectiveness-transferability-bias-audit-2026-10-12

Expanding genomic secondary findings can trigger a concentrated treatment-cost cascade—model the budget impact before policy expands.
https://www.mattheneus.com/editorial/pubmed-genomic-secondary-findings-budget-impact-treatment-cost-concentration-2026-10-10
#HTA #HealthEconomics